IRCT201107217085N1 IRCT 2011-11-22 Vice Chancellery for Reserch and Technology, Isfahan University of Medical Sciences, Isfahan, Iran Noradrenalin versus Midodrin-Octerotid in Hepatorenal Syndrome Noradrenalin versus the combination of Midodrine and Octreotide in the treatment of patients with Hepatorenal syndrome type 1 and 2 referred to Alzahra Hospital since 2011 to 2012 2011-09-23 anticipated 22 Complete https://irct.ir/trial/7509 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Hepatorenal Syndrome type 1 & 2. Intervention 1: One group is treated with Noradrenalin infusion of 0.1 microgram per kilogram. The dose is escalated every 4 hours by 0.05 microgram per kilogram up to the maximum dose of 0.7 microgram per kilogram or until 10 millimeter increase in the mean arterial pressure. The drug is continued until creatinine is reached less than 1.5 milligram per deciliter or until 15 days. Intervention 2: The other group is treated with Octereotide infusion of 25 microgram per hour and oral Midodrin of 5 milligram three times a day up to the maximum dose of 45 milligram per day or until Mean arterial pressure is increased by 15 millimeter. The treatment is continued until creatinine is reached less than 1.5 milligram per deciliter or 15 days is elapsed.